Articles related to KIDNEY DISEASE

Semaglutide has been shown to reduce the risk of major kidney disease events and cardiovascular mortality in patients with type 2 diabetes and chronic kidney disease.

In patients with type 2 diabetes and stage 5 chronic kidney disease, the use of SGLT2 inhibitors is associated with a lower risk of initiating dialysis and experiencing major cardiovascular events, providing a promising therapeutic avenue in a population at elevated risk.

Acquired reactive perforating collagenosis, characterized by pruritic eruptions and systemic associations, often manifests in patients with diabetes or chronic kidney disease, underscoring the necessity for holistic patient assessment in dermatological evaluations.

In patients with chronic kidney disease, the elevated troponin challenge necessitates a nuanced approach, integrating serial measurements and clinical context to discern acute coronary syndrome from chronic elevations, thereby informing targeted management strategies.

Urine color can serve as a valuable diagnostic tool, offering insights into a patient’s hydration level and potential underlying health issues. Understanding these variations is essential for timely and accurate diagnosis.

SGLT-2 inhibitors have emerged as a cornerstone in managing HFrEF and CKD, demonstrating substantial reductions in cardiovascular and renal adverse outcomes. This class of medications is reshaping the therapeutic approach in patients with these comorbid conditions, providing a dual benefit that was once considered challenging to achieve.